Dehydroepiandrosterone (DHEA) and 3␤-hydroxy-5␣-androstan-17-one (epiandrosterone, EpiA) are both precursors for 7␣-and 7␤-hydroxylated metabolites in the human brain. These 7-hydroxylated derivatives were shown to exert anti-glucocorticoid and neuroprotective effects. When these steroids are administered per os to humans, the first organ encountered is the liver, where extensive metabolism takes place. The objective of this work was to assess the cofactor dependence and metabolism of DHEA, EpiA, and their 7-hydroxylated derivatives in S9 fractions of human liver, using a radiolabeled steroid substrate for quantification and gas chromatography-mass spectrometry for identification. The best transformation yields were obtained with NADPH and were larger in female than in male. Results showed that both DHEA and EpiA mainly transformed into their 17␤-hydroxylated derivatives, 7-or 16␣- 
Dehydroepiandrosterone (DHEA) has been termed "neurosteroid" after evidence was found for its production in the brain of gonadectomized and adrenalectomized rats (Corpechot et al., 1981) , and this neurosteroid was also found in the human brain (Brown et al., 2000b; Lanthier and Patwardhan, 1986; WeillEngerer et al., 2002) . It is doubtful whether DHEA is important for neuroprotection because larger amounts exist in the cerebrospinal fluid of patients with neurodegenerative diseases (Brown et al., 2000a; Kim et al., 2003) and because of the absence of DHEAmediated protective effects obtained in vitro (Pringle et al., 2003) . This raised the question of DHEA metabolism and the putative neuroprotective effects of the metabolites produced. Previous research on the liver and brain showed that DHEA 7␣-hydroxylation takes place in both organs (Doostzadeh and Morfin, 1996; Doostzadeh et al., , 1998 Rose et al., 1997) . All studies provided evidence for a P450-catalyzed process. The screening of hippocampal transcripts in rats, mice, and humans led to the identification of a new cytochrome P450 (termed CYP7B1) and to its cDNA production (Stapleton et al., 1995; Rose et al., 1997; Schwarz et al., 1997; Wu et al., 1999; Morfin and Starka, 2001; Trincal et al., 2002) . The presence of CYP7B1 in the liver was demonstrated (Schwarz et al., 1998; Wu et al., 1999 ) and found to be responsible for the 7␣-hydroxylation of most 3␤-hydroxysteroids, including oxysterols, pregnenolone, DHEA, 5-androstene-3␤,17␤-diol, 5␣-androstane-3␤,17␤-diol, estradiol (Rose et al., 1997) , 3␤-hydroxy-5␣-pregnan-20-one (Strö mstedt et al., 1993) , and epiandrosterone (EpiA) (Lafaye et al., 1999; Kim et al., 2004b) .
Investigations of DHEA metabolism in mouse brain tissue provided evidence for the NADPH-dependent formation of almost equal quantities of both 7␣-hydroxylated and 7␤-hydroxylated transformation products . No P450 was found to be responsible for 7␤-hydroxy-DHEA production. Investigations with knockout mice for CYP7B1 showed that neither 7␣-hydroxy-DHEA nor 7␤-hydroxy-DHEA was produced (Lathe, 2002) , which implied that the CYP7B1 was a requisite for their production. The question arising on the process responsible for 7␤-hydroxy-DHEA has been tentatively addressed recently with data showing that in liver microsomes, the 11␤-hydroxysteroid dehydrogenases (11␤-HSDs) and unknown enzymes may be involved in an oxidoreduction process transforming 7␣-hydroxy-DHEA into 7-oxo-DHEA and 7␤-hydroxy-DHEA (Robinzon et al., 2003; Kim et al., 2004a) .
Neuroprotection exerted by 7␣-hydroxy-DHEA was first suggested after work with rat hippocampal cell cultures and comparison with aromatization products (Jellinck et al., 2001) . More recently, a test for that hypothesis was developed on a model of hypoxia-induced neu-mM concentration of the NADPH-regenerating system in 2% NaHCO 3 containing NADP ϩ , 7.09 mM glucose 6-phosphate, and 1.5 U/ml glucose-6-phosphate dehydrogenase. Identical conditions were used for control incubations with either 10-min boiled or unsupplemented S9 fractions. The tubes were left open during the course of incubation with shaking at 37°C for 20 min. Incubations were stopped after the addition of 0.5 ml of acetone followed by 4 ml of ethyl acetate. The extraction process continued with 4 ml of ethyl acetate and was repeated three times. Counting of the aqueous phase and dpm computation were carried out with an Amersham Biosciences AB (Uppsala, Sweden) 1209 rack beta liquid scintillation counter fitted with external standard equipment and automatic background subtraction (PerkinElmer, France).
Steroid Metabolite Separation and Quantification. Ethyl acetate extracts recovered from incubations with 4-14 C-labeled steroids were analyzed by thin-layer chromatography (TLC) on ready to use silica-60-coated glass plates (Merck) developed once either in ethyl acetate or in benzene/ethanol (9:1 v/v). In these systems, the metabolites of each steroid substrate tested were clearly separated, except for the 7␣-hydroxy-EpiA/7␤-hydroxy-EpiA mixture. Radiosteroids were located on the plates by autoradiography, recovered by scrapping with a razor blade, and eluted from the gel with methanol/ethyl acetate (1:9 v/v). Autoradiography of the thin-layer chromatograms with BioMax Light X-ray film (Eastman Kodak, Rochester, NY) was performed to locate the radio-steroids on TLC silica gel plates. Quantitative scanning of the plates was carried out with use of a Berthold automatic TLC-linear analyzer (PerkinElmer, France). High performance liquid chromatography (HPLC) was used in response to the poor TLC separation of the 7␣-hydroxy-EpiA/7␤-hydroxy-EpiA mixture. The Shimadzu LC-6A HPLC apparatus was fitted with a 100-l injection loop and a 26-cm C 18 -coated silica (5-m) column (Ultrabase; Societé Françoise Chromato Colonne) from Interchim (Montluçon, France) that was maintained at 30°C. Elution was carried out at 0.7 ml ⅐ min Ϫ1 with methanol/water (6:4 v/v) and collection of 0.25-ml portions split for GC/MS identification and for quantification by counting.
Steroid Metabolite Identification (GC/MS Analysis). R f values after TLC and retention times after HPLC were compared with those of authentic standards, and each major steroid metabolite was identified by GC/MS analysis with an Agilent Technologies (Massy, France) system including a 6890N network GC apparatus coupled with a 5973 network mass selective detector. Trimethylsilyl (TMS) ether derivatives of authentic steroid references and unidentified steroid metabolites were prepared just before analysis by reacting the dried steroids in 30 l of pyridine with 20 l of bis-silyl-trifluoroacetic acid containing 1% trimethylchlorosilane (Pierce Chemical, Rockford, IL) at 60°C for 60 min. TMS derivatives were dried and taken up in toluene for injection on an HP-5MS fused silica capillary column (30 m, 0.25-mm i.d.) coated at 5% with a phenylmethylsiloxane phase (0.25-m thickness). The oven temperature was programmed from 80°C for 1 min and then with a temperature increment of 30°C/min, up to 240°C. After 8 min at 240°C, the temperature was increased again at 30°C/min up to 300°C and then maintained up to the end of the run. The column was directly coupled to the quadrupole mass spectrometer ionization chamber, where the source was set at 230°C and the energy of bombarding electrons was at 70 eV. The mass abundance was determined two times per second by scanning from m/z 50 to m/z 800. The identity of each of the major steroid metabolites produced by the human liver S9 fractions was assessed by comparison of their retention time and mass spectra with those of the 25 authentic reference compounds. The assessment used the match-up function on the built-in library in the MSD Chemstation software D.01.00 (Agilent Technologies).
Results
Preliminary experiments were carried out with [4-14 C]DHEA or [4-14 C]EpiA and 0.75 mg of protein from human liver S9 fractions with use of either a 10 mM Tris-HCl buffer (pH 7.4) or a 66.7 mM phosphate buffer (pH 7.4), both containing 1 mM EDTA, and in the presence of the NADPH-regenerating system, or NADH, NAD ϩ , and NADP ϩ . The best yields were obtained with the phosphate buffer that was then selected for all other incubations. In these conditions, the control incubations carried out with 10-min boiled S9 fractions or in the absence of cofactors yielded no transformation products for any of the steroid substrates used.
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at ASPET Journals on September 8, 2017 dmd.aspetjournals.org Downloaded from DHEA Metabolism. After GC/MS comparison, the metabolites produced were identified with 7␣-hydroxy-DHEA, 7␤-hydroxy-DHEA, 7-oxo-DHEA, 16␣-hydroxy-DHEA, and 5-androstene-3␤,17␤-diol authentic steroids (Table 1) . One minor metabolite was not separated from 7-oxo-DHEA after TLC; however, after GC under a TMS derivative form of the mixture, it could not be formally identified. Fragments in its mass spectrum were those of a monohydroxylated DHEA derivative, thus leading to its qualification as n-hydroxy-DHEA (Table 1 ). The liver S9 fractions from both male and female donors transformed DHEA mainly under reductive cofactor supplementation. The largest yields in metabolism concerned 16␣-hydroxy-DHEA production that was obtained after NADPH supplementation. For 5-androstene-3␤,17␤-diol production, NADH was the cofactor required. Both oxidized cofactors gave poor yields in transformation products or none at all (Table 2) . Reductive transformation yields were the largest with female liver S9 fractions, except for 5-androstene-3␤,17␤-diol production, where male liver S9 fractions gave better yields (Table 2 ). This implied that the liver contents with P450s responsible for DHEA hydroxylation were greater in females than in males, whereas the male liver contained more of the NADH-dependent 17␤-hydroxysteroid oxidoreductase than in the female liver. The female liver S9 fractions were used for the studies of 7␣-and 7␤-hydroxy-DHEA metabolism because of the equivalent DHEA metabolism in both sexes and higher yields obtained in females.
7␣-Hydroxy-DHEA Metabolism. The three metabolites produced by female liver S9 fractions were identified with 7␤-hydroxy-DHEA, 7-oxo-DHEA, and 5-androstene-3␤,7␣,17␤-triol authentic steroids ( Table 1 ). The largest yields of 7␤-hydroxy-DHEA were obtained under NADPH conditions, whereas those of 7-oxo-DHEA required NADP ϩ (Table 2 ). This suggests that a NADPH-driven oxidoreduction system is responsible for the production of 7␤-hydroxy-DHEA. The production of 5-androstene-3␤,7␣,17␤-triol required the action of a 17␤-hydroxysteroid oxidoreductase. This enzyme was almost as active with NADP(H) as with NAD(H), which indicates either that the 7␣-hydroxy-DHEA substrate could be reduced by both cofactors or that two isoforms of the same enzyme were present with near equivalent activities.
7␤-Hydroxy-DHEA Metabolism. Only two metabolites were produced by female liver S9 fractions under NADPH supplementation, and these were identified with 7-oxo-DHEA and 5-androstene-3␤,7␤,17␤-triol authentic steroids (Table 1) . No trace of 7␣-hydroxy-DHEA was detected, thus implying that the 7-oxo-DHEA produced could not be reduced back into the 7␣-epimer. As for 7␣-hydroxy-DHEA, the production of 5-androstene-3␤,7␤,17␤-triol required the action of a 17␤-hydroxysteroid oxidoreductase that was active under NADPH conditions (Table 2) .
EpiA Metabolism. After a GC/MS comparison, the metabolites produced were identified with 7␤-hydroxy-EpiA, 16␣-hydroxy-EpiA, 5␣-androstane-3␤,17␤-diol, and 5␣-androstane-3,17-dione authentic steroids (Table 3) . One minor metabolite was not formally identified because of the lack of appropriate reference and it was not investigated further (Table 3 ). The liver S9 fractions from both male and female donors transformed EpiA mainly under reductive conditions. The largest yields in metabolism were obtained after NADPH supplementation, except for 5␣-androstane-3␤,17␤-diol and 5␣-androstane-3,17-dione, where NADH and NAD ϩ were the required cofactors, respectively (Table 4) . No trace of 7␣-hydroxy-EpiA was obtained, in contrast to low but significant amounts of 7␤-hydroxyEpiA. In the female, both 16␣-hydroxy-EpiA and 5␣-androstane-3␤,17␤-diol were the major metabolites produced under NADPH and NADH supplementation, respectively. The same cofactor dependence occurred under oxidative conditions resulting in a larger production of 5␣-androstane-3,17-dione in the female than in the male. This suggested that a 3␤-hydroxysteroid oxidoreductase was present in larger quantities in the female liver as opposed to the male. The female liver S9 fractions were used for the studies of 7␣-and 7␤-hydroxy-EpiA metabolism because of the equivalent EpiA metabolic patterns in both sexes and the larger yields obtained in females, 7␣-Hydroxy-EpiA Metabolism. Neither TLC nor HPLC permitted the separation of the two metabolites produced after incubation with female liver S9 fractions (Table 4) . After a TMS derivative formation, the two metabolites were separated by GC and identified with 7␤-hydroxy-EpiA and 5␣-androstane-3␤,7␣,17␤-triol authentic 
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dmd.aspetjournals.org steroids ( Table 3 ). The 7␤-hydroxy-EpiA/5␣-androstane-3␤,7␣,17␤-triol ratio obtained after GC/MS separation indicated that 7␤-hydroxy-EpiA only was produced in the presence of NADP ϩ , whereas increasing amounts of 5␣-androstane-3␤,7␣,17␤-triol appeared under NADPH, NAD ϩ , and NADH conditions. No trace of 7-oxo-EpiA was detected; therefore, the putative oxidoreduction of 7␣-hydroxy-EpiA into 7␤-hydroxy-EpiA could only be suspected. Reductive conditions were necessary for a significant production of 5␣-androstane-3␤,7␣,17␤-triol by the two NADPH-dependent and NADH-dependent 17␤-hydroxysteroid oxidoreductases.
7␤-Hydroxy-EpiA Metabolism. Two metabolites were obtained after incubation with female liver S9 fractions and were identified with 7␣-hydroxy-EpiA and 5␣-androstane-3␤,7␤,17␤-triol authentic steroids by GC/MS as shown in Table 3 . Significant and major yields of 7␣-hydroxy-EpiA were obtained under reductive and oxidative conditions, which led us to suspect an oxidoreductive mechanism (Table 4 ). The highest amounts of 5␣-androstane-3␤,7␤,17␤-triol were produced under NADH supplementation, thus inferring the presence of a NADH-dependent 17␤-hydroxysteroid oxidoreductase.
Discussion
We used human liver S9 fractions that contained both hepatic microsomes and cytosol with active steroid-metabolizing enzymes. The age of the donors was not provided. Compared with microsomes and cytosol, S9 fractions offer a more complete although lower representation of the steroid metabolism, since they contain both phase I and phase II activity (Brandon et al., 2003) . Research into DHEA metabolism helped to link our data with those of others and consequently validate our approach for the studies of EpiA and 7-hydroxysteroid metabolism. The supplementation of S9 fractions with cofactors was necessary (Brandon et al., 2003) and allowed the sorting out of enzymes through their reductive or oxidative activities and dependence upon NAD(H) or NADP(H). The use of a NADPHregenerating system helped with the hydroxylation process carried out by the microsomal cytochromes P450, which are well known in the liver. Thus, the 7␣-hydroxylation of DHEA was already shown in human liver (Wu et al., 1999; Fitzpatrick et al., 2001; Miller et al., 2004 ) and described as resulting from catalysis by CYP3A4 (Fitzpatrick et al., 2001; Miller et al., 2004) and CYP7B1 (Wu et al., 1999) . Since CYP7B1 carries out the 7␣-hydroxylation on most of the 3␤-hydroxysteroid substrates (Rose et al., 1997) , it was surprising to find no trace of 7␣-hydroxy-EpiA in EpiA digests. We have reported that other human tissue preparations 7␣-hydroxylated EpiA (Lafaye et al., 1999) and found recently that the human CYP7B1 expressed in yeast microsomes carried out the 7␣-hydroxylation of EpiA with a K M higher than that of DHEA (Kim et al., 2004b) . The fact that 7␤-hydroxy-EpiA was produced instead of 7␣-hydroxy-EpiA suggests that one liver P450 carried out the 7␤-hydroxylation of EpiA. At present, there is no documentation to support a P450-mediated 7␤-hydroxylation of EpiA. However, the 7␤-hydroxylation of DHEA by CYP3A4 is documented (Stevens et al., 2003; Miller et al., 2004) , and this P450 may also carry out the 7␤-hydroxylation of EpiA in the liver. We also observed a 7␣/7␤ interconversion. This was reported as resulting from an oxidoreduction process catalyzed by 11␤-hydroxysteroid dehydrogenase isoforms using both 7␣-hydroxy-DHEA and 7␤-hydroxy-DHEA via the 7-oxo-DHEA (Robinzon et al., 2003) . Our data confirm such a paradigm, with DHEA yielding at least equivalent levels of 7␣-and 7␤-hydroxy-DHEA produced, together with large amounts of 7-oxo-DHEA. In turn, 7␣-hydroxy-DHEA and 7␤-hydroxy-DHEA were both precursors for 7-oxo-DHEA. Concerning 7␣-hydroxy-EpiA and 7␤-hydroxy-EpiA, their interconversion was obtained without evidence for 7-oxo-EpiA production. It is then possible that either the 11␤-hydroxysteroid dehydrogenase-catalyzed oxidoreduction process reported for 7-hydroxy-DHEA (Robinzon et al., 2003) may extend to the 7-hydroxylated EpiA substrates, or that an unknown epimerase is involved in the interconversion process.
Our findings of significant amounts of 16␣-hydroxy-DHEA and 16␣-hydroxy-EpiA in DHEA and EpiA digests imply the presence of CYP3A4 and CYP3A5 in liver S9 fractions. These two P450s were described as responsible for DHEA 16␣-hydroxylation (Niwa et al., 1998; Miller et al., 2004) rather than CYP3A7, which is found in human endometrium, placenta, and fetal liver (Miller et al., 2004) . Even though the adult human liver carries out the 16␣-hydroxylation of DHEA (Miller et al., 2004) , no direct evidence is available for the 16␣-hydroxylation of EpiA. We found a significantly larger production of 16␣-hydroxy-DHEA and 16␣-hydroxy-EpiA in females than dmd.aspetjournals.org in males, thus implying sex differences in the P450s responsible. Provided that EpiA 16␣-hydroxylation is carried out by CYP3A4, this finding is in accordance with the higher levels of CYP3A4 found in the human female liver (Wolbold et al., 2003) . In contrast, no unknown metabolite that could be 16␣-hydroxylated was found in digests of 7␣-and 7␤-hydroxy-DHEA or 7␣-and 7␤-hydroxy-EpiA, thus inferring that the 7-hydroxylated derivatives of DHEA and EpiA were not substrates for the 16␣-hydroxylase. The human liver contains several isoforms of the 17␤-hydroxysteroid oxidoreductase that differ in their dependence for the NAD(H) or NADP(H) cofactors (Blomquist, 1995) . In this study, all of the substrates tested were 17-oxo-steroids and readily transformed into their 17␤-hydroxy derivatives under the reductive conditions using either NADPH or NADH. This is in contrast with the results obtained with liver microsomes (Fitzpatrick et al., 2001; Miller et al., 2004) , where no 17␤-reduction of DHEA was obtained. Since the liver S9 fractions contain both microsomes and cytosol, we may suspect the 17␤-reducing enzyme to be cytosolic. Thus, male and female livers contained both a NADP(H)-dependent and a NAD(H)-dependent 17␤-hydroxysteroid oxidoreductase almost equivalently active on the DHEA substrate. In contrast, EpiA metabolism showed none of the NADP(H)-dependent 17␤-hydroxysteroid oxidoreductase activity in the female, but a NAD(H)-dependent 17␤-hydroxysteroid oxidoreductase activity was significantly larger in the female than in the male liver. Whether these differences result from different affinities of the steroid substrates for the 17␤-hydroxysteroid oxidoreductases or from different 17␤-hydroxysteroid oxidoreductase isoforms cannot be stated from the present results.
We found that EpiA was oxidized at the 3␤-position. This is in contrast to DHEA, which was unchanged, in agreement with reports using human liver microsomes (Fitzpatrick et al., 2001; Miller et al., 2004) . DHEA oxidation into 4-androstene-3,17-dione implies a twostep mechanism catalyzed by the NAD-dependent 3␤-hydroxysteroid dehydrogenase/isomerase that is commonly found in steroidogenic tissues rather than in the liver. In contrast, the presence in human liver homogenates of a microsomal 3␤-hydroxysteroid oxidoreductase has been reported (Pirog and Collins, 1999) .
The present data obtained with the 7-hydroxylated EpiA and 7-hy-FIG. 1. Summary of the metabolites identified after DHEA (A) or EpiA (B) incubations with human liver S9 fractions. All structures were identified by GC/MS except those indicated with question marks. The liver enzymes responsible for the production of metabolites are: 1, CYP7B1 or CYP3A4; 1, CYP3A4; 2, CYP3A4 or CYP3A5; 3, unknown hydroxylating enzyme; 4, 17␤-hydroxysteroid dehydrogenase; 5, 11␤-HSD1; 6, unknown oxidoreductase; 7, 3␤-hydroxysteroid dehydrogenase.
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dmd.aspetjournals.org Downloaded from droxylated DHEA metabolism in liver are of importance when the neuroprotective action of these steroids is considered. The putative use of 7␤-hydroxy-EpiA as a neuroprotective agent is presently sought, and it is of importance to know whether, once administered per os, the liver enzymes will dramatically decrease the blood-borne quantities brought up to the brain. Our data show that more than 90% of the 7␤-hydroxy-EpiA incubated are left intact, and that both the 5␣-androstane-3␤,7␤,17␤-triol and the 7␣-hydroxy-EpiA produced may be transformed back into 7␤-hydroxy-EpiA. The same findings apply to 7␤-hydroxy-DHEA. One shortcoming of our present data concerns the putative action of phase II enzymes that would produce water-soluble conjugated derivatives. Recovery yields after ethyl acetate extraction of the digests were between 96 and 99%, and the possible steroid metabolites in the water phase were not examined. Yet, the formation of conjugates requires the addition of specific exogenous cofactors (Brandon et al., 2003) , and this was not done in the present study. Nevertheless, the present findings are indicative of the metabolites produced in both sexes, even if transposable to neither whole homogenates nor an in vivo situation. Our findings about the metabolism of DHEA, EpiA, and 7-hydroxylated derivatives by human liver S9 fractions are summarized in Fig. 1 . The main originalities in these findings are that the 7-hydroxylated derivatives of DHEA and EpiA are not substrates for cytochrome P450-hydroxylating enzymes in human liver, and that both 7␣-and 7␤-epimers are converted into each other. The putative involvement of the microsomal 11␤-hydroxysteroid dehydrogenases through an oxidoreductive process involving the production of a 7-oxo intermediate is appealing and justifies further investigations with use of the purified human enzymes.
